Excessive Daytime Sleepiness, but Not Insomnia Is Associated With Dyslipidaemia in Patients With Obstructive Sleep Apnoea Participating in ESADA.
Abstract
Excessive daytime sleepiness (EDS) as well as insomnia have been associated with a higher risk for cardiovascular disease in patients with obstructive sleep apnoea (OSA). The link is not fully understood but may involve dyslipidaemia. The aim of the study was to analyse if the EDS and insomnia phenotypes were associated with deranged serum lipid values in patients with OSA recruited from a European real-world cohort. Patients with OSA and a full lipid profile participating in the ESADA database were analysed (n = 12,153). Based on their symptoms, they were categorised into EDS (n = 3123), EDS + insomnia (n = 2091), insomnia (n = 2862) and non-EDS non-insomnia (n = 4077) subgroups. Nonparametric ANCOVA adjusted for age, body mass index, smoking, alcohol, study site, apnoea-hypopnoea index and time spent with saturation below 90%, followed by Dunn's test and Bonferroni correction, was used to compare lipid values between the groups. The analyses were also performed in predefined subgroups. There were significant differences in total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C) and triglyceride (TG) values between the four groups (all p < 0.01). Patients with EDS had the highest TC (5.11 ± 1.08 vs. 5.00 ± 1.10, 5.03 ± 1.12, 5.04 ± 1.10 mmol/L, EDS vs. EDS + insomnia, insomnia, non-EDS non-insomnia, respectively), LDL-C (3.12 ± 0.97 vs. 3.01 ± 0.98, 3.02 ± 1.00, 3.09 ± 0.98 mmol/L) and TG (1.86 ± 1.04 vs. 1.76 ± 0.97, 1.69 ± 0.90, 1.75 ± 0.93 mmol/L) values…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 12,153 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.